Design Therapeutics, Inc. DSGN Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s investment proceeds?
- Design Therapeutics, Inc. (DSGN) reported investment proceeds of $45M in Q1 2026.
- How has Design Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Design Therapeutics, Inc.'s investment proceeds decreased by 52.4% year-over-year, from $94.49M to $45M.
- What is the long-term trend for Design Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s investment proceeds has grown at a 74.3% compound annual growth rate (CAGR), from $34.16M to $314.89M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.